We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Testing for Drug-Resistant Bacteria Before Prostate Biopsy Reduces Infection

By LabMedica International staff writers
Posted on 31 Dec 2014
Print article
Image: The VITEK 2 system for rapid microbial identification and antibiotic susceptibility testing (Photo courtesy of bioMérieux).
Image: The VITEK 2 system for rapid microbial identification and antibiotic susceptibility testing (Photo courtesy of bioMérieux).
Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure and the cultures test for antibiotic-resistant E. coli can be used to direct the selection of antimicrobial prophylaxis used for the procedure.

Transrectal ultrasonography–guided prostate biopsy (TRUSBx) is one of the most commonly performed outpatient urologic procedures and infection is a well-established risk, including urinary tract infection (UTI), prostatitis, bacteremia, sepsis, with well-recognized complications such as hematuria, rectal bleeding, and hematospermia.

Clinicians at the Rhode Island Hospital (Providence, RI, USA) performed a retrospective study of 487 total patients, receiving prostate biopsies from February 2013 to February 2014; 314 received preprocedure rectal cultures and 173 did not. Average ages were 62.7 and 64.1 years, respectively. There was no difference in mean prostate-specific antigen value, Charlson comorbidity score, or ethnicity.

Rectal swabs were collected in the clinic, typically less than one month before TRUSBx. For fluoroquinolone resistance testing, swabs were directly cultured on both MacConkey agar with 1 μg/mL ciprofloxacin and on blood agar plates and incubated at 35 °C for 48 hours. Antibiotic susceptibilities were determined using the automated VITEK 2 machine (bioMérieux, Inc.; Hazelwood, MO, USA).

The scientists found that found that 12.8% of the patients had preexisting, drug-resistant E. coli on the rectal swab cultures. They noted that there was a lower likelihood of post-biopsy infections and a decreased adjusted risk of infectious complications for patients receiving prophylaxis based on pre-biopsy rectal swab culture results as compared to those patients who underwent the procedure without the pre-biopsy rectal swab cultures, but the differences did not reach statistical significance because of the study size. Cultures from two of these patients grew fluoroquinolone-resistant Acinetobacter junii and Pseudomonas aeruginosa.

The patients who did not have the pre-biopsy rectal swab cultures done and who developed an infectious complication after the biopsy had longer hospitalizations for post-procedure infection, three days versus 1.6 days and 40% required continued outpatient treatment with intravenous antibiotics for those infections, compared with the 16.6% of the group treated with culture-directed antibiotics.

Jessica Dai, MD, the lead author of the study said, “As men are increasingly opting for active surveillance of prostate cancer, infectious risks associated with prostate biopsy are becoming particularly relevant. We hypothesized that the incidence of infections would decline after instituting this new screening process, and they did. Not only did we see that, we also met our secondary aim of establishing the local incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase (ESBL)-producing bacteria in rectal swab cultures.” The study was published on November 20, 2014, in the journal Urology.

Related Links:
Rhode Island Hospital
bioMérieux, Inc. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.